Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 24:9:65-71.
doi: 10.2147/LCTT.S166320. eCollection 2018.

1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT

Denise Albano  1 , Thomas Bilfinger  1 , Barbara Nemesure  2
Affiliations

1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT

Denise Albano et al. Lung Cancer (Auckl). .

Abstract

Background: Lobectomy has traditionally been recommended for fit patients diagnosed with early-stage non-small-cell lung cancer (NSCLC). Recently, however, stereotactic body radiotherapy (SBRT) has been introduced as an alternative treatment option. The purpose of this investigation is to compare survival outcomes for individuals with stage I/II NSCLC treated with lobectomy vs SBRT.

Methods: This retrospective study included 191 patients (100 surgery, 91 SBRT) identified through the Lung Cancer Evaluation Center, Stony Brook, NY, between 2008 and 2012. Survival and recurrence rates were compared using Kaplan-Meier curves, log-rank tests, and Cox proportional hazard models to adjust for possible confounders. A subset of cases was propensity-matched to address potential differences in health status between groups.

Results: 1-, 3-, and 5-year survival outcomes were significantly better among patients undergoing lobectomy vs SBRT. Survival rates at 3 years were 92.8% and 59.0% (p<0.001) in the 2 groups, respectively. Propensity-matched analyses indicated similar findings. Recurrence rates were likewise lower among patients undergoing surgery (7.1% vs 21.0%, p<0.01 at 3 years); however, statistical significance was not maintained in the propensity-matched analysis.

Conclusion: These findings add to a growing evidence base supporting the use of lobectomy vs SBRT in the treatment of lung cancer among healthy, early-stage NSCLC patients.

Keywords: SBRT; lobectomy; survival.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
5-Year K–M survival curves for patients treated by lobectomy vs SBRT. Abbreviations: K–M, Kaplan–Meier; SBRT, stereotactic body radiation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reck M, Popat S, Reinmuth N, et al. ESMO Guidelines Working Group Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27–iii39. - PubMed
    1. ACS ACS 2018 Facts and Figures. 2018. [Accessed August 2, 2018]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
    1. Rusthoven CG, Kavanagh BD, Karam SD. Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data. Ann Transl Med. 2015;3(11):149. - PMC - PubMed
    1. NCCN NCCN Guidelines 2017. 2017. [Accessed August 30, 2016]. Available from: https://www.nccn.org/patients/guidelines/lung_screening/index.html#16.
    1. Vansteenkiste J, De Ruysscher D, Eberhardt WE, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi89–vi98. - PubMed

LinkOut - more resources